ALACT.PA
Acticor Biotech SAS [ALACT.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALACT.PA Stock Summary
Top 10 Correlated ETFs
ALACT.PA
Top 10 Correlated Stocks
ALACT.PA
In the News
ALACT.PA Financial details
Company Rating
Buy
Market Cap
35.78M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
26 Oct 2023
P/E
-1.83
Forward P/E
-
PEG
-
P/S
-
P/B
-13.54
P/C
-
P/FCF
-3.12
Quick Ratio
0.98
Current Ratio
1.75
Debt / Equity
19.15
LT Debt / Equity
11.8
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-7.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
22.62%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-25%
SMA50
-40%
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-129%
ROE
-379%
ROC
-2.42%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
13.33M
Shs Float
5.71M
-
-
-
-
Target Price
-
52W Range
2.72-11.0
52W High
-73.64%
52W Low
+45%
RSI
31
Rel Volume
0.66
Avg Volume
3.49K
Volume
2.3K
Perf Week
2.84%
Perf Month
-25.45%
Perf Quarter
-45.08%
Perf Half Y
-48.03%
-
-
-
-
Beta
-0.367
-
-
Volatility
0.04%, 0.42%
Prev Close
0%
Price
2.9
Change
0%
ALACT.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.57 | -0.48 | -0.73 | -1.7 | -1.58 | |
| Operating cash flow per share | -0.52 | -0.41 | -0.64 | -1.77 | -1.15 | |
| Free cash flow per share | -0.52 | -0.41 | -0.64 | -1.77 | -1.15 | |
| Cash per share | 0.97 | 1.22 | 0.72 | 1.46 | 0.63 | |
| Book value per share | 0.59 | 0.86 | 0.16 | 1.42 | -0.21 | |
| Tangible book value per share | 0.59 | 0.79 | 0.1 | 1.42 | -0.28 | |
| Share holders equity per share | 0.59 | 0.86 | 0.16 | 1.42 | -0.21 | |
| Interest debt per share | 0.13 | 0.12 | 0.25 | 0.42 | 0.82 | |
| Market cap | 74.35M | 74.35M | 74.35M | 35.63M | 74.45M | |
| Enterprise value | 65.36M | 62.6M | 69.32M | 26.99M | 75.72M | |
| P/E ratio | -12.41 | -14.71 | -9.62 | -2.7 | -4.48 | |
| Price to sales ratio | 1.49K | 0 | 0 | 0 | 0 | |
| POCF ratio | -13.58 | -17.39 | -11.03 | -2.59 | -6.15 | |
| PFCF ratio | -13.44 | -17.32 | -10.94 | -2.59 | -6.15 | |
| P/B Ratio | 11.92 | 8.23 | 43.33 | 3.23 | -33.19 | |
| PTB ratio | 11.92 | 8.23 | 43.33 | 3.23 | -33.19 | |
| EV to sales | 1.31K | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -11.52 | -13.42 | -9.33 | -2.27 | -5.04 | |
| EV to operating cash flow | -11.94 | -14.64 | -10.29 | -1.96 | -6.26 | |
| EV to free cash flow | -11.81 | -14.58 | -10.21 | -1.96 | -6.25 | |
| Earnings yield | -0.08 | -0.07 | -0.1 | -0.37 | -0.22 | |
| Free cash flow yield | -0.07 | -0.06 | -0.09 | -0.39 | -0.16 | |
| Debt to equity | 0.19 | 0.13 | 1.49 | 0.25 | -3.51 | |
| Debt to assets | 0.11 | 0.07 | 0.23 | 0.15 | 0.61 | |
| Net debt to EBITDA | 1.58 | 2.52 | 0.68 | 0.73 | -0.08 | |
| Current ratio | 2.71 | 2.8 | 1.59 | 4.16 | 1.75 | |
| Interest coverage | -37.15 | -58.68 | -95.9 | -19.98 | -19.74 | |
| Income quality | 0.91 | 0.85 | 0.88 | 1.09 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 31.06 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 81.84 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.05 | 0.06 | 0.04 | 0.06 | |
| Capex to operating cash flow | 0.01 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | -1.16 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.37 | -0.03 | -0.38 | -0.14 | -0.07 | |
| Stock based compensation to revenue | 0.68 | 0 | 0 | 0 | 0 | |
| Graham number | 2.75 | 3.04 | 1.64 | 7.35 | 2.75 | |
| ROIC | -0.78 | -0.48 | -1.74 | -0.9 | -2.82 | |
| Return on tangible assets | -0.53 | -0.34 | -0.75 | -0.77 | -1.36 | |
| Graham Net | 0.48 | 0.62 | -0.16 | 0.58 | -0.81 | |
| Working capital | 7.01M | 9.29M | 3.74M | 12.82M | 5.04M | |
| Tangible asset value | 6.24M | 8.32M | 1M | 10.31M | -2.96M | |
| Net current asset value | 5.95M | 8.09M | 817K | 10.01M | -3.45M | |
| Invested capital | 0.19 | 0.13 | 1.49 | 0.25 | -3.51 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 905.5K | 1.07M | 2.17M | 2.87M | 4.08M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.96 | -0.56 | -4.5 | -1.2 | 7.42 | |
| Capex per share | -0.01 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | -4.21M | -8.64M | -2.31M | 1.26M | -908K | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 1.12 | 0.25 | 0.6 | -3.51 | 19.15 | |
| Debt to assets | 0.35 | 0.15 | 0.23 | 0.61 | 0.49 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 3.11 | 4.16 | 2.29 | 1.75 | 1.52 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.05 | 0.04 | 0.06 | 0.06 | 0.05 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 8.35M | 12.82M | 5.77M | 5.04M | 4.43M | |
| Tangible asset value | 3.4M | 10.31M | 3.6M | -2.96M | -345K | |
| Net current asset value | 3.26M | 10.01M | 3.22M | -3.45M | -895K | |
| Invested capital | 1.12 | 0.25 | 0.6 | -3.51 | 19.15 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ALACT.PA Frequently Asked Questions
What is Acticor Biotech SAS stock symbol ?
Acticor Biotech SAS is a FR stock and trading under the symbol ALACT.PA
What is Acticor Biotech SAS stock quote today ?
Acticor Biotech SAS stock price is $2.9 today.
Is Acticor Biotech SAS stock public?
Yes, Acticor Biotech SAS is a publicly traded company.
Company Profile
- Volume Average 3.49K
- Market Capitalization 35.78M
- Employee 29
- CEO Dr. Gilles Avenard M.D.
- Headquarters Paris,FR
- IPO Date 2021-11-01
-
Website
https://acticor-biotech.com 
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
